“Background:… Povidone iodine (PVP-I) is an antiseptic that has been used for over 150 years. It is already proved that different concentration of PVP-I can deactivate COVID-19 virus.
Methodology: In this randomized controlled clinical trial, out of 1113 patients, 606 patients were enrolled and divided in 2 groups by randomization after taken consents. In Gr-A, 303 patients underwent mouthwash/gargle, nasal drops and eye drops with 1% povidone iodine 4 hourly for 4 weeks as well as symptomatic treatment according to need. In Gr-B, 303 patients were advised mouthwash/gargle, nasal cavity and eye wash with lukewarm water 4 hourly for 4 weeks and symptomatic treatment according to need…
Results: … In group A (patients used PVP-I), only 2.64% (N-8) patient is RT-PCR positive on the 7th day, whereas in group B (patients used lukewarm water), it is 70.30% (N-213) (Table 2, Gr- A & B) (p>0.05). Data of Table 3 (Gr-A&B) shows that 3.30% (N-10) hospitalized patients of group A needed oxygen support (by mechanical ventilatorand/or high flow nasal cannula and/or non rebreather mask and/or face mask and/or nasal cannula) but 20.79% (N-63) patients of group B needed oxygen support. Mortality rate is high[er] 5.6% (N-17) in group B than 0.66% (N-2) in group A. The differences were statistically significant (P<0.05).”
About the Journal https://www.banglajol.info/index.php/BRC/about
Bioresearch Communications (BRC) is an open access international journal only online version. Abstracts and full texts of all articles published in the journals can be read online without any form of restriction... Our readers can copy, distribute, and use their attributed research for non-commercial purpose free of charge. Our journal retains copyright of the articles through a Creative Commons attribution license (CC-BY-NC 4.0).